The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.

Abstract

OBJECTIVE:

To evaluate the effect of phytotherapeutic agent, Eviprostat, administered after the establishment of nonbacterial prostatitis (NBP) on the stroma-to-epithelium ratio (S/E ratio), inflammatory scores, tissue macrophage infiltration, and cytokines and chemokines levels in prostate tissue and urine.

MATERIALS AND METHODS:

Ten-month-old male Wistar rats were castrated and exposed to 17-beta-isomer of estradiol for 30 days to induce NBP. Twenty-five NBP rats were divided into 5 groups: (1) NBP (0) rats sacrificed immediately after the establishment of NBP; (2,3) NBP (30)/control (CTL) and NBP (30)/Eviprostat (EVI) rats fed without or with 0.1% Eviprostat under estradiol-free for 30 days, respectively; and (4,5) NBP (60)/CTL and NBP (60)/EVI rats fed without or with 0.1% Eviprostat under estradiol-free for 60 days, respectively. The S/E ratio, inflammatory scores, and the number of macrophage infiltration in the prostate were assessed. Concentrations of cytokines and chemokines in prostatic tissue and urine were measured by enzyme-linked immunosorbent assay.

RESULTS:

The S/E ratio was significantly increased with time until 60 days under estradiol-free condition (P <.001). The S/E ratio and the inflammatory scores in NBP (60)/EVI was significantly lower than that of NBP (60)/CTL (P <.001, and P = .022, respectively). The mean tissue concentration of chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in NBP (60)/CTL was significantly higher than that in NBP (0) (P = .016), whereas, there was no difference between NBP (60)/EVI and NBP (0). Furthermore, urinary CCL2/MCP-1 was significantly decreased in NBP (60)/EVI as compared with NBP (0) (P = .028).

CONCLUSION:

Eviprostat suppresses the stromal proliferation and inflammation in the rat prostate after the establishment of NBP at least partly owing to inhibitory effect on CCL2/MCP-1 production in the prostate.

• Authors: Shinsuke Shibuya, Zhang Xia, Mikio Sugimoto, Nobufumi Ueda, Reiji Haba, Yoshiyuki Kakehi
• Journal: Urology (Urology) Vol. 83 Issue 3 Pg. 528-34 (Mar 2014) ISSN: 1527-9995 [Electronic] United States
• PMID: 24581515 (Publication Type: Journal Article)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Chemokine CCL2
• Chemokine CCL3
• Chemokine CXCL1
• Chemokines
• Drug Combinations
• Interleukin-1beta
• Plant Extracts
• Urological Agents
• Ethamsylate
• Estradiol
• eviprostat

Topics

• Animals
• Cell Proliferation (drug effects)
• Chemokine CCL2 (metabolism)
• Chemokine CCL3 (metabolism)
• Chemokine CXCL1 (metabolism)
• Chemokines (metabolism, urine)
• Disease Models, Animal
• Drug Combinations
• Epithelial Cells (drug effects)
• Estradiol
• Ethamsylate (pharmacology)
• Interleukin-1beta (metabolism)
• Macrophages
• Male
• Orchiectomy
• Plant Extracts (pharmacology)
• Prostate (drug effects, metabolism, pathology)
• Prostatitis (drug therapy, metabolism, pathology)
• Rats
• Rats, Wistar
• Stromal Cells (drug effects)
• Urological Agents (pharmacology)